

Commercial & HealthCare Exchange PA Criteria
Effective: November 11, 2020

Prior Authorization: Ongentys

Products Affected: Ongentys (octreotide) delayed-release oral capsules

Medication Description: Opicapone is a selective and reversible inhibitor of catechol-o-methyltransferase (COMT). Physiological substrates of COMT include DOPA, catecholamines (dopamine, norepinephrine, and epinephrine), and their hydroxylated metabolites. When decarboxylation of levodopa is prevented by carbidopa, COMT becomes the major metabolizing enzyme for levodopa, catalyzing its metabolism to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD).

Covered Uses: Adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing "off" episodes

Exclusion Criteria:

1. Concomitant use of non-selective monoamine oxidase (MAO) inhibitors.
2. Pheochromocytoma, paraganglioma, or other catecholamine secreting neoplasms

Required Medical Information:

1. Diagnosis
2. Previous therapies tried and failed

Age Restrictions: 18 years of age and older

Prescriber Restrictions: Prescribed by, or in consultation with a neurologist.

Coverage Duration: 12 months

Other Criteria:

Parkinson's Disease

- A. Patient has a diagnosis of Parkinson's disease; **AND**
- B. Patient is experiencing "off" episodes; **AND**
- C. Patient is currently on carbidopa/levodopa; **AND**
- D. Patient has tried and failed, or has a contraindication or intolerance to two of the following:
 - a. MAO-B inhibitor (e.g. rasagiline, selegiline); **AND**
 - b. COMT inhibitor (e.g. entacapone)

References:

1. Ongentys [product insert]. Neurocrine Biosciences, Inc., San Diego, CA. April 2020.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	10/22/2020